INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression, and exhibits anticancer activity in ccne1-amplified cancers and cdk4/6i-resistant intraductal breast cancer models.

INX-315 (30-300 nM, 24 hours) treatment of OVCAR3 and MKN1 cells effectively inhibited cell cycle progression by downregulating the phosphorylation of retinoblastoma protein (Rb) [1].
INX-315 (0.3 nM - 10 μM, 6 days) treatment of CCNE1-amplified ovarian cancer cell lines significantly suppressed cell proliferation [1].

In the BALB/c nude mouse model of gastric adenocarcinoma, oral administration of INX-315 at a dose of 100 mg/kg (twice daily for 56 consecutive days) effectively inhibited tumor growth [1].
In the OVCAR3 ovarian cancer Parazacco spilurus subsp. In a Spilurus xenograft model, intraperitoneal injection of INX-315 at doses of 100 mg/kg (twice daily) or 200 mg/kg (once daily) for 42 days demonstrated significant tumor suppression and was well tolerated [2].
In the GA0103 gastric cancer Parazacco spilurus subsp. spilurus xenograft model, intraperitoneal injection of INX-315 at a dose of 100 mg/kg (twice daily for 56 consecutive days) exhibited notable antitumor activity with favorable tolerability [2].